98%
921
2 minutes
20
Objectives: Sleep disorders are part of the symptomatology of rheumatoid arthritis (RA) patients and are related to disease characteristics and comorbidities. The study describes sleep quality among RA patients and identifies predictors of optimal sleep.
Methods: Patients whose data were analysed were identified from the recent-onset RA cohort initiated in 2004. In 2010, the Medical Outcome Study Sleep Scale (MOS-SS) was incorporated into the patients' assessments. Up to December 2019, the cohort comprised 187 patients with at least one MOS-SS application (in 78 patients at cohort entry) and six months of outcomes behaviour (cumulative) previous to the MOS-SS application: DAS28-ESR, pain-VAS, fatigue, HAQ-DI, SF-36, treatment (corticosteroids, DMARDs/patient and adherence), Charlson score, and major depressive episodes. A trained data abstractor retrospectively reviewed their charts. Multiple logistic regression analysis estimated odds ratios (95% confidence interval) to define baseline and cumulative variables predictive of optimal sleep (dichotomised variable derived from the quantity of sleep dimension of the MOS-SS).
Results: At the first MOS-SS application, patients were primarily middle-aged women with short disease duration and low disease activity. They scored higher on the "snoring" and "sleep non-adequacy" MOS-SS dimensions. There were 96 patients (51.3%) with optimal sleep. Lower baseline BMI, better baseline fatigue score, longer follow-up at the clinic, and better SF-36 physical summary score were predictors of optimal sleep (mental summary score also remained in the model when switched to the physical summary score).
Conclusions: Optimal sleep is achieved by half of the RA patients and predicted by BMI, patient-reported outcomes, and follow-up.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.55563/clinexprheumatol/j88k7a | DOI Listing |
Clin Kidney J
September 2025
Hypertension is a pervasive and progressive complication in chronic kidney disease (CKD) patients, affecting up to 90% of those in advanced stages or on dialysis. A particularly insidious aspect of this condition is nocturnal hypertension, characterized by high blood pressure (BP) during sleep and a blunted or absent nighttime BP dipping-phenomena associated with accelerated CKD progression and increased cardiovascular risk. Despite its strong prognostic significance, nocturnal hypertension remains underdiagnosed due to limited use of ambulatory BP monitoring.
View Article and Find Full Text PDFClin Rehabil
September 2025
Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.
ObjectiveTo adapt and modify the successful SIESTA (Sleep for Inpatients: Empowering Staff to Act) sleep-promoting hospital protocol to an acute stroke rehabilitation setting.DesignThis study utilized a mixed methods design, involving qualitative surveys and interviews. Needs assessment and staff interviews informed the development of the adapted protocol, SIESTA-Rehab.
View Article and Find Full Text PDFChest
September 2025
Flinders Health and Medical Research Institute/Adelaide Institute for Sleep Health, Flinders University, Bedford Park, South Australia, Australia.
Background: Hypoglossal nerve stimulation (HNS) to treat obstructive sleep apnea (OSA) currently requires placement of a cuff or 'saddle' electrode around or adjacent to the hypoglossal nerve(s). Limitations for this therapy include cost, invasiveness, and variable efficacy.
Research Question: Can HNS applied via percutaneous implantation of a linear, multi-pair electrode array restore airflow to airway narrowing and/or obstruction, and improve airway collapsibility in people with OSA?
Study Design And Methods: Participants with OSA undergoing drug induced sleep endoscopy with propofol were instrumented with an epiglottic pressure catheter, nasal mask and pneumotachograph.
Neuropsychopharmacol Rep
September 2025
Department of Pharmaceutical Sciences, School of Pharmacy at Narita International University of Health and Welfare, Narita, Chiba, Japan.
Benzodiazepine and non-benzodiazepine hypnotics (Z-drugs) are known risk factors for adverse events, including delirium and falls. Although formularies are intended to promote appropriate prescribing, few comprehensive studies have assessed their clinical impact in the context of sleep medications. This study aimed to evaluate changes in hypnotic prescribing patterns and associated clinical outcomes following the implementation of a sleep medication formulary.
View Article and Find Full Text PDFAlzheimers Dement
September 2025
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, New South Wales, Australia.
Introduction: Risperidone is approved for behaviors and psychological symptoms of dementia (BPSD), despite modest efficacy and known risks. Identifying responsive symptoms, treatment modifiers, and predictors is crucial for personalized treatment.
Method: A one-stage individual participant data meta-analysis of six randomized controlled trials (risperidone: n = 1009; placebo: N = 712) was conducted.